Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) EBITDA (2016 - 2025)

Historic EBITDA for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.3 million.

  • Utah Medical Products' EBITDA fell 5485.49% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 3220.09%. This contributed to the annual value of $12.6 million for FY2024, which is 2992.34% down from last year.
  • Latest data reveals that Utah Medical Products reported EBITDA of $2.3 million as of Q3 2025, which was down 5485.49% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, Utah Medical Products' EBITDA peaked at $6.9 million during Q4 2022, and registered a low of $884000.0 during Q4 2024.
  • In the last 5 years, Utah Medical Products' EBITDA had a median value of $3.4 million in 2021 and averaged $3.6 million.
  • Per our database at Business Quant, Utah Medical Products' EBITDA skyrocketed by 32981.19% in 2021 and then crashed by 8428.72% in 2024.
  • Over the past 5 years, Utah Medical Products' EBITDA (Quarter) stood at $4.1 million in 2021, then skyrocketed by 67.53% to $6.9 million in 2022, then decreased by 19.0% to $5.6 million in 2023, then plummeted by 84.29% to $884000.0 in 2024, then skyrocketed by 155.09% to $2.3 million in 2025.
  • Its EBITDA was $2.3 million in Q3 2025, compared to $4.9 million in Q2 2025 and $3.8 million in Q1 2025.